艾媒咨询 | 2026-2027年中国医疗美容产业发展与消费趋势报告

作为消费升级与“颜值经济”深化发展的重要赛道，医疗美容产业持续受益于生物材料、光电技术及数字化平台对产品研发、精准营销、服务交付与术后管理等环节的全方位赋能，其效能已从单一的非手术类项目延伸至再生医学、抗衰老管理与轻医美连锁化运营等场景革新。当前，行业版图内上游药械制造、中游医疗服务、下游互联网平台及供应链服务等多元模式竞合交织，机构对医生资源、合规产品与用户口碑的争夺日趋白热化，监管框架从专项整治向常态化、精细化规范演进，安全与合规成为竞争底线。在政策端，促进医疗健康消费、规范医美行业发展及支持生物医药与高端医疗器械创新的信号持续释放，为医疗美容企业在产品研发、模式创新及品牌建设中注入了新的活力。纵观行业发展脉络，医疗美容产业正经历从营销驱动向产品力与品牌价值创造的跃迁，材料创新与医疗服务标准化的广度深度将成为进一步发展的关键支点。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026-2027年中国医疗美容产业发展与消费趋势报告》数据显示，医疗美容产业高度集中于以长三角为核心的经济发达与消费活跃地带，既折射出区域间在消费能力、医生人才、机构密度及监管执行等方面的深层差异，也催生了特色化、差异化的区域医美消费板块。头部企业在市值、营收和利润方面都占据优势，TOP10营收集中度较高，前三名营收占比达74.63%，整体行业营收结构呈现少数龙头企业领跑、中小企业差异化竞争的格局。其中聚焦功能性护肤品和医美手术的企业发展较快，反映出行业从规模化向精细化转型阶段。
通过对典型企业的研究，可以更直观地了解医疗美容板块各具特色的布局和差异化的发展路径。华熙生物以其在透明质酸原料、功能性护肤品及医美终端产品上的全产业链布局，展现了生物活性材料研发与品牌化运营协同的路径；爱美客作为注射填充类医美产品龙头，其经营情况与估值波动深度绑定于合规产品放量及再生材料等新品获批节奏，研发投入与渠道管控能力对其持续成长构成了关键支撑；朗姿股份作为医美服务连锁布局的代表，凭借旗下医美机构品牌在轻医美及手术类项目上的区域深耕，实现了从时尚消费向医疗美容服务的跨界协同发展。三家企业的资产结构、盈利质量与估值逻辑虽有差异，但共同指向了精细化运营、持续创新与医疗安全及服务价值的深度挖掘。
As a key sector driving the ongoing evolution of consumption upgrading and the "Aesthetic Economy," the medical aesthetics industry continues to benefit from the comprehensive empowerment provided by biomaterials, optoelectronic technologies, and digital platforms across various stages—including product development, precision marketing, service delivery, and post-procedure management. Its scope has expanded beyond standalone non-surgical procedures to encompass innovative applications such as regenerative medicine, anti-aging management, and the chain-based operation of light aesthetic treatments. Currently, the industry landscape features a complex interplay of competitive and collaborative dynamics across diverse business models—ranging from upstream pharmaceutical and medical device manufacturing to midstream healthcare services and downstream internet platforms and supply chain services. Competition among institutions for physician resources, compliant products, and customer reputation has intensified significantly; meanwhile, the regulatory framework has evolved from targeted Special Rectification Campaign initiatives toward more normalization and refined standardization, with safety and compliance becoming the baseline for competitive advantage. On the policy front, ongoing signals aimed at stimulating healthcare and wellness consumption, regulating the medical aesthetics industry, and supporting innovation in biopharmaceuticals and high-end medical devices have injected new vitality into medical aesthetics enterprises' efforts in product development, business model innovation, and brand building. Overall, the medical aesthetics industry is undergoing a transformative shift—from being marketing-driven to focusing on the creation of product competitiveness and brand value; in this context, material innovation and the standardization of healthcare services—both in breadth and depth—will serve as pivotal leverage points for further growth.
According to the latest "2026–2027 China Medical Cosmetology Industry Development and Consumption Trend Report" released by iiMedia Research, a globally leading third-party data mining and analysis firm specializing in the new economy sector, the medical cosmetology industry is highly concentrated in economically developed and consumer-active regions, particularly around the Yangtze River Delta. This concentration not only reflects deep-seated regional disparities in consumer purchasing power, physician talent pool, institutional density, and regulatory enforcement but has also given rise to specialized and differentiated regional medical cosmetology consumption segments. Leading enterprises hold advantages in terms of market capitalization, revenue, and profitability; the top 10 companies account for a high concentration of total revenue, with the top three companies representing 74.63% of the industry's total revenue. The overall industry revenue structure features a landscape where a few leading enterprises drive growth, while small and medium-sized enterprises engage in differentiated competition. Among these, companies focusing on functional skincare products and medical cosmetic procedures are experiencing rapid growth, reflecting the industry's transition from a scale-driven model to a precision-driven one.
By studying representative enterprises, one can gain a more intuitive understanding of the distinctive strategic layouts and differentiated development pathways within the medical cosmetology sector. Huaxi Biotech demonstrates a synergistic approach to the R&D of bioactive materials and brand-driven operations through its comprehensive industrial chain layout covering hyaluronic acid raw materials, functional skincare products, and medical aesthetics end-products; Aimeike, as a leading player in injectable filling-based medical aesthetics products, sees its operational performance and valuation fluctuations closely tied to the pace of mass-market adoption of compliant products and the approval timeline for new products such as regenerative materials; its R&D investment and channel management capabilities serve as key supports for its sustainable growth; Langzi Co., Ltd., representing a company with a strategic chain-based medical aesthetics service network, has achieved cross-sector synergistic development—shifting from fashion-oriented consumer goods to medical aesthetics services—through its regional deepening of operations across light medical aesthetics and surgical procedures under its medical aesthetics institution brands. Although these three companies differ in their asset structures, profit quality, and valuation logic, they collectively point to refined operational practices, continuous innovation, and the deep exploration of medical safety and service value.